New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePal-GHK vs Larazotide Acetate

Pal-GHK vs Larazotide Acetate

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Pal-GHK
Recovery & Repair
Larazotide Acetate
Summary
Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
Half-Life
Extended (lipid depot in stratum corneum)
Local gut action; minimal systemic exposure
Admin Route
Topical
Oral
Research
Typical Dose
0.005–0.1% in formulation
0.5-2 mg
Frequency
Once or twice daily
3x daily
Key Benefits
  • Stimulates collagen I and III synthesis in dermis
  • Reduces the appearance of fine lines and wrinkles
  • Improves skin elasticity and firmness
  • Inhibits collagenase (MMP-1) to preserve existing collagen
  • Enhances wound healing and skin repair
  • Well-tolerated in anti-aging serums and creams
  • Directly reduces intestinal tight junction permeability
  • Clinical efficacy in celiac disease (Phase 3 trials)
  • Reduces systemic inflammation from gut permeability
  • Targets root cause of leaky gut (Zonulin pathway)
  • Local gut action without systemic absorption
  • Potential application in IBS, IBD, autoimmune conditions
Side Effects
  • Generally very well-tolerated
  • Rare skin irritation at very high concentrations
  • Possible formulation-dependent comedogenicity
  • Headache (mild, dose-dependent)
  • Nausea (rare)
  • Well-tolerated overall in clinical trials
Stacks With